272 Capital LP Lowers Stock Position in Definitive Healthcare Corp. (NASDAQ:DH)

272 Capital LP decreased its position in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) by 39.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 677,940 shares of the company's stock after selling 436,140 shares during the period. Definitive Healthcare comprises 2.6% of 272 Capital LP's holdings, making the stock its 15th largest holding. 272 Capital LP owned approximately 0.59% of Definitive Healthcare worth $2,786,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its holdings in Definitive Healthcare by 3,652.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company's stock worth $29,000 after purchasing an additional 6,794 shares in the last quarter. Ieq Capital LLC bought a new position in Definitive Healthcare in the 4th quarter valued at approximately $51,000. KLP Kapitalforvaltning AS acquired a new stake in Definitive Healthcare during the 4th quarter worth approximately $54,000. Two Sigma Securities LLC bought a new stake in Definitive Healthcare during the 4th quarter worth approximately $56,000. Finally, Quantbot Technologies LP increased its position in Definitive Healthcare by 5,305.5% in the 4th quarter. Quantbot Technologies LP now owns 17,730 shares of the company's stock valued at $73,000 after acquiring an additional 17,402 shares during the period. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DH. Barclays decreased their price objective on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a report on Monday, March 3rd. The Goldman Sachs Group decreased their price target on Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $5.35.

Definitive Healthcare Trading Up 2.8 %

Shares of NASDAQ:DH traded up $0.08 during mid-day trading on Wednesday, hitting $2.73. The company had a trading volume of 289,537 shares, compared to its average volume of 852,467. The company has a market capitalization of $294.20 million, a PE ratio of -0.88, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48. Definitive Healthcare Corp. has a one year low of $2.15 and a one year high of $7.47. The firm has a fifty day moving average price of $2.70 and a 200 day moving average price of $3.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). The company had revenue of $62.29 million for the quarter, compared to the consensus estimate of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. As a group, research analysts forecast that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.